ZYME Relative Valuation
ZYME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZYME is overvalued; if below, it's undervalued.
Historical Valuation
Zymeworks Inc (ZYME) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.84 is considered Undervalued compared with the five-year average of -3.99. The fair price of Zymeworks Inc (ZYME) is between 121.39 to 128.99 according to relative valuation methord. Compared to the current price of 23.10 USD , Zymeworks Inc is Undervalued By 80.97%.
Relative Value
Fair Zone
121.39-128.99
Current Price：23.10
80.97%
Undervalued
-28.70
PE
1Y
3Y
5Y
216.60
EV/EBITDA
Zymeworks Inc. (ZYME) has a current EV/EBITDA of 216.60. The 5-year average EV/EBITDA is 6.00. The thresholds are as follows: Strongly Undervalued below -73.81, Undervalued between -73.81 and -33.91, Fairly Valued between 45.90 and -33.91, Overvalued between 45.90 and 85.81, and Strongly Overvalued above 85.81. The current Forward EV/EBITDA of 216.60 falls within the Strongly Overvalued range.
-16.72
EV/EBIT
Zymeworks Inc. (ZYME) has a current EV/EBIT of -16.72. The 5-year average EV/EBIT is -3.45. The thresholds are as follows: Strongly Undervalued below -11.01, Undervalued between -11.01 and -7.23, Fairly Valued between 0.33 and -7.23, Overvalued between 0.33 and 4.11, and Strongly Overvalued above 4.11. The current Forward EV/EBIT of -16.72 falls within the Strongly Undervalued range.
20.84
PS
Zymeworks Inc. (ZYME) has a current PS of 20.84. The 5-year average PS is 17.86. The thresholds are as follows: Strongly Undervalued below -35.19, Undervalued between -35.19 and -8.67, Fairly Valued between 44.38 and -8.67, Overvalued between 44.38 and 70.90, and Strongly Overvalued above 70.90. The current Forward PS of 20.84 falls within the Historic Trend Line -Fairly Valued range.
-45.02
P/OCF
Zymeworks Inc. (ZYME) has a current P/OCF of -45.02. The 5-year average P/OCF is -15.54. The thresholds are as follows: Strongly Undervalued below -505.96, Undervalued between -505.96 and -260.75, Fairly Valued between 229.66 and -260.75, Overvalued between 229.66 and 474.87, and Strongly Overvalued above 474.87. The current Forward P/OCF of -45.02 falls within the Historic Trend Line -Fairly Valued range.
17.77
P/FCF
Zymeworks Inc. (ZYME) has a current P/FCF of 17.77. The 5-year average P/FCF is -3.70. The thresholds are as follows: Strongly Undervalued below -36.80, Undervalued between -36.80 and -20.25, Fairly Valued between 12.85 and -20.25, Overvalued between 12.85 and 29.40, and Strongly Overvalued above 29.40. The current Forward P/FCF of 17.77 falls within the Overvalued range.
Zymeworks Inc (ZYME) has a current Price-to-Book (P/B) ratio of 6.25. Compared to its 3-year average P/B ratio of 2.16 , the current P/B ratio is approximately 188.66% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about 153.05% higher. Zymeworks Inc (ZYME) has a Forward Free Cash Flow (FCF) yield of approximately -3.29%. Compared to its 3-year average FCF yield of 3.30%, the current FCF yield is approximately -199.56% lower. Relative to its 5-year average FCF yield of -12.21% , the current FCF yield is about -73.07% lower.
6.25
P/B
Median3y
2.16
Median5y
2.47
-3.29
FCF Yield
Median3y
3.30
Median5y
-12.21
Competitors Valuation Multiple
The average P/S ratio for ZYME's competitors is 453.43, providing a benchmark for relative valuation. Zymeworks Inc Corp (ZYME) exhibits a P/S ratio of 20.84, which is -95.4% above the industry average. Given its robust revenue growth of 72.59%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ZYME increased by 70.21% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 16.00M to 27.61M.
The secondary factor is the P/E Change, contributed 59.57%to the performance.
Overall, the performance of ZYME in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
Frequently Asked Questions
Is Zymeworks Inc (ZYME) currently overvalued or undervalued?
Zymeworks Inc (ZYME) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.84 is considered Undervalued compared with the five-year average of -3.99. The fair price of Zymeworks Inc (ZYME) is between 121.39 to 128.99 according to relative valuation methord. Compared to the current price of 23.10 USD , Zymeworks Inc is Undervalued By 80.97% .
What is Zymeworks Inc (ZYME) fair value?
ZYME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zymeworks Inc (ZYME) is between 121.39 to 128.99 according to relative valuation methord.
How does ZYME's valuation metrics compare to the industry average?
The average P/S ratio for ZYME's competitors is 453.43, providing a benchmark for relative valuation. Zymeworks Inc Corp (ZYME) exhibits a P/S ratio of 20.84, which is -95.40% above the industry average. Given its robust revenue growth of 72.59%, this premium appears sustainable.
What is the current P/B ratio for Zymeworks Inc (ZYME) as of Jan 09 2026?
As of Jan 09 2026, Zymeworks Inc (ZYME) has a P/B ratio of 6.25. This indicates that the market values ZYME at 6.25 times its book value.
What is the current FCF Yield for Zymeworks Inc (ZYME) as of Jan 09 2026?
As of Jan 09 2026, Zymeworks Inc (ZYME) has a FCF Yield of -3.29%. This means that for every dollar of Zymeworks Inc’s market capitalization, the company generates -3.29 cents in free cash flow.
What is the current Forward P/E ratio for Zymeworks Inc (ZYME) as of Jan 09 2026?
As of Jan 09 2026, Zymeworks Inc (ZYME) has a Forward P/E ratio of -28.70. This means the market is willing to pay $-28.70 for every dollar of Zymeworks Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Zymeworks Inc (ZYME) as of Jan 09 2026?
As of Jan 09 2026, Zymeworks Inc (ZYME) has a Forward P/S ratio of 20.84. This means the market is valuing ZYME at $20.84 for every dollar of expected revenue over the next 12 months.